Medicinova Inc (MNOV) 6.27 $MNOV MediciNova Announces

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Medicinova Inc (MNOV) 6.27 $MNOV

MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana
GlobeNewswire - Wed May 25, 6:00PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that two abstracts detailing novel findings from further analysis of the completed clinical trial of MN-166 (ibudilast) in alcohol dependence have been accepted for presentation at the 39 Annual Scientific Meeting of the Research Society on Alcoholism to be held June 25-29, 2016 at the Hyatt Regency New Orleans in New Orleans, LA.
MNOV: 6.27 (+0.07)

MediciNova Announces Interim Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada
GlobeNewswire - Wed Apr 20, 5:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced that principal investigator Dr. Benjamin Rix Brooks, Director, Carolinas HealthCare System's Neuromuscular/ALS-MDA Center, will present interim data today from MediciNova's ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) at the American Academy of Neurology (AAN) 68th Annual Meeting at the Vancouver Convention Centre in Vancouver, BC, Canada. The interim analysis, which was performed by an independent statistician consultant, includes a total of 25 subjects without non-invasive ventilator support who completed the 6-month double-blind treatment period with complete spirometry (respiratory function test) data.
MNOV: 6.27 (+0.07)

MediciNova, Inc. (NASDAQ: MNOV) - Analyst Coverage Initiated; Report by Broad Street
ACCESSWIRE - Mon Apr 04, 7:02AM CDT
LA JOLLA, CA / ACCESSWIRE / April 4, 2016 / MediciNova, Inc. (NASDAQ: MNOV) a biopharmaceutical company focused on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market, recently announced that the medical journal Drug and Alcohol Dependence has published a new article regarding positive findings from a completed Phase 1b clinical trial of MN-166 (ibudilast) in methamphetamine dependence. The article, which was written by Matthew J. Worley, Keith G. Heinzerling, and colleagues at the University of California, Los Angeles (UCLA), reports that MN-166 (ibudilast) was shown to significantly reduce the subjective effects of methamphetamine in subjects diagnosed with methamphetamine dependence. Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, "We are very pleased that the detailed results of the first clinical trial evaluating MN-166 in methamphetamine-dependent subjects have been published. Based on the reported positive findings from this study, we continue to work in collaboration with researchers at UCLA on a much larger ongoing Phase 2 clinical study to evaluate MN-166 in methamphetamine-dependent subjects."
MNOV: 6.27 (+0.07)

MediciNova Announces Publication of Positive Findings from Completed Phase 1b Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence
GlobeNewswire - Wed Mar 30, 6:00PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the medical journal Drug and Alcohol Dependence has published a new article regarding positive findings from a completed Phase 1b clinical trial of MN-166 (ibudilast) in methamphetamine dependence. The article, which was written by Matthew J. Worley, Keith G. Heinzerling, and colleagues at the University of California, Los Angeles (UCLA), reports that MN-166 (ibudilast) was shown to significantly reduce the subjective effects of methamphetamine in subjects diagnosed with methamphetamine dependence.
MNOV: 6.27 (+0.07)

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 in China
GlobeNewswire - Sun Mar 27, 6:00PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a notice of allowance from the Chinese Patent Office for a new patent which covers MN-001 (tipelukast).
MNOV: 6.27 (+0.07)

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia
GlobeNewswire - Wed Mar 23, 6:00PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia.
MNOV: 6.27 (+0.07)

FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for Progressive Multiple Sclerosis
GlobeNewswire - Tue Mar 22, 5:09AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of MN-166 (ibudilast) for the treatment of patients with progressive multiple sclerosis (progressive MS). Progressive MS includes both primary progressive MS (PPMS) and secondary progressive MS (SPMS). Fast Track is a process designed to facilitate the development and expedite the review of drugs that are intended to treat serious or life-threatening diseases and demonstrate the potential to address unmet medical needs for such diseases. An important feature of the FDA's Fast Track program is that it emphasizes frequent communication between the FDA and the sponsor throughout the entire drug development and review process to improve the efficiency of product development. Accordingly, Fast Track status can potentially lead to a shortened timeline to ultimate drug approval.
MNOV: 6.27 (+0.07)

LifeSci Capital Initiates Coverage of MediciNova
ACCESSWIRE - Mon Mar 14, 12:57PM CDT
Targeting Neurological, Fibrotic, and Respiratory Diseases with Unmet Medical Needs; Report Available here: www.lifescicapital.com/equity-research/medicinova/
MNOV: 6.27 (+0.07)

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
GlobeNewswire - Mon Mar 07, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of amyotrophic lateral sclerosis (ALS).
MNOV: 6.27 (+0.07)

MediciNova Announces Presentation of Data From the Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas
GlobeNewswire - Sun Feb 07, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that principal investigator Sandra Comer, Ph.D., Professor, Department of Psychiatry, Columbia University and New York State Psychiatric Institute (NYSPI), will present results of the completed Phase 2 trial which evaluated MN-166 (ibudilast) in patients with opioid dependence. Dr. Comer's presentation will be held during the symposium titled, "Glial and Neuroinflammatory Modulators for Attenuating Some Abuse-Related Effects of Drugs," at the Behavior, Biology and Chemistry Annual Meeting and Symposium.
MNOV: 6.27 (+0.07)

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH With Fibrosis
GlobeNewswire - Wed Jan 27, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of advanced NASH (nonalcoholic steatohepatitis) with fibrosis.
MNOV: 6.27 (+0.07)

FDA Grants Rare Pediatric Disease Designation to MediciNova's MN-166 (ibudilast) for the Treatment of Krabbe Disease
GlobeNewswire - Mon Jan 18, 5:16PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to MN-166 (ibudilast) for treatment of Type 1 - Early Infantile Krabbe disease. Under the FDA's rare pediatric disease priority review voucher program, the sponsor may be eligible for a voucher that can be used to obtain a priority review for a subsequent human drug application. The FDA has previously granted orphan drug designation to MN-166 (ibudilast) for treatment of Krabbe disease.
MNOV: 6.27 (+0.07)

MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride in Europe
GlobeNewswire - Wed Jan 13, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced receipt from the European Patent Office of a notice of intent to allow patent for MN-029 (denibulin) di-hydrochloride.
MNOV: 6.27 (+0.07)

FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis
GlobeNewswire - Wed Dec 16, 5:00AM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for MN-166 (ibudilast) for the treatment of patients with amyotrophic lateral sclerosis (ALS). Fast Track is a process designed to facilitate the development and expedite the review of drugs that are intended to treat serious or life-threatening diseases and demonstrate the potential to address unmet medical needs for such diseases. An important feature of the FDA's Fast Track program is that it emphasizes frequent communication between the FDA and the sponsor throughout the entire drug development and review process to improve the efficiency of product development. Accordingly, Fast Track status can potentially lead to a shortened timeline to ultimate drug approval.
MNOV: 6.27 (+0.07)

MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride in China
GlobeNewswire - Mon Dec 14, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a notice of allowance for a new patent from the Chinese Patent Office which covers MN-029 (denibulin) di-hydrochloride.
MNOV: 6.27 (+0.07)

MediciNova Announces Positive Interim Safety and Clinical Outcomes Data From Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 26th International Symposium on ALS/MND in Orlando, FL
GlobeNewswire - Sun Dec 13, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced that principal investigator Dr. Benjamin Rix Brooks, Director, Carolinas HealthCare System's Neuromuscular/ALS-MDA Center, today presented interim data from MediciNova's ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) at the 26th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) in Orlando, FL. The interim analysis includes a total of 36 subjects, and 33 of those subjects completed 6 months of treatment on study drug (MN-166 or placebo in a 2:1 ratio).
MNOV: 6.27 (+0.07)

MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting
GlobeNewswire - Wed Dec 09, 4:30PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced that Dr. Daniel Roche today presented results based on the completed study which evaluated the safety and efficacy of MN-166 (ibudilast) in alcohol use disorder (Dr. Lara Ray, UCLA, Principal Investigator) at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting.
MNOV: 6.27 (+0.07)

MediciNova Announces Presentation Regarding Clinical Trial of MN-166 (ibudilast) in ALS at the 6th Annual California ALS Pac10 and Research Network Meeting at UCSD, La Jolla, Californiaã??
GlobeNewswire - Sun Dec 06, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced that Dr. Yuichi Iwaki, President and CEO, has accepted an invitation to make a presentation regarding the ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) at the 6th Annual California ALS Pac10 and Research Network Meeting which will be held at the Sanford Consortium for Regenerative Medicine, UCSD, La Jolla, California.
MNOV: 6.27 (+0.07)

Evaluating the Technicals - Research on Hudson Technologies, Retractable Technologies, Spark Networks and MediciNova
ACCESSWIRE - Wed Dec 02, 6:45AM CST
NEW YORK, NY / ACCESSWIRE / December 02, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Hudson Technologies Inc. (NASDAQ: HDSN), Retractable Technologies Inc. (NYSE MKT: RVP), Spark Networks Inc. (NYSE MKT: LOV) and MediciNova Inc. (NASDAQ: MNOV). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
HDSN: 4.86 (-0.06), MNOV: 6.27 (+0.07), RVP: 2.40 (-0.01), LOV: 1.78 (unch)

MediciNova to Initiate Clinical Trial Evaluating MN-001 in NASH Patients With Hypertriglyceridemia
GlobeNewswire - Thu Nov 19, 5:00AM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it is initiating a clinical trial to investigate MN-001 (tipelukast) for the treatment of hypertriglyceridemia in NASH patients. The principal investigator is Paul J. Pockros, MD, Division Head of Gastroenterology and Hepatology at Scripps Clinic, and the trial will be primarily conducted at U.S. medical centers within SC Liver Research Consortium (SCLRC), an organization of hepatology and gastroenterology clinical research specialists which includes Scripps Clinic, University of Washington Medical Center, University of California San Diego, and Cleveland Clinic.
MNOV: 6.27 (+0.07)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 120

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 115

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
Another Nine's A9OS Puts Software at Center of Golf

Updated Category News Views 63

A golf simulator chain is trying to turn the boring plumbing into its sharpest club. Another Nine’s A9OS is not merely a booking widget dressed up for a franchise brochure; it is meant to run the whole 24/7 operation, from payments and door access to cameras, simulator support and guest help. That ambition deserves attention because this is exactly where a staff-free...

Continue Reading
Markley’s Lowell Campus Turns Data Land Into Arboretum

Updated Category News Views 43

Server halls rarely get credited with restoring a landscape, which is why Markley’s Lowell campus caught my eye. On November 18, 2026, the company said its Lowell data center campus had earned Level I arboretum accreditation from the ArbNet Arboretum Accreditation Program. ArbNet describes itself as the only international accreditation program specifically for arboreta,...

Continue Reading
Jumia’s Breakeven Retreat Invites Legal Scrutiny

Updated Category News Views 63

Jumia’s credibility problem did not arrive wearing a disguise. The company spent much of 2026 telling investors that a fourth-quarter Adjusted EBITDA breakeven was still on the table, then discarded that target after reporting third-quarter results. For holders of NYSE:JMIA, that kind of reversal stings because the promise was not some stray talking point; it was...

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 87

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading
Yoodli's No. 9 Ranking Signals Enterprise AI Traction

Updated Category News Views 102

Ninth place can be easy to dismiss until you notice the company is sitting near the top of a 500-name growth list. Yoodli's No. 9 position on Deloitte's 2026 Technology Fast 500 is a meaningful signal that its AI-based coaching and workforce-skills pitch is getting traction inside large organizations. It is not a revenue disclosure, it is not a valuation marker, and...

Continue Reading
Paladone Tests LEGO's Everyday Collectibles Pull Abroad

Updated Category News Views 139

A glowing minifigure lamp is not exactly a macroeconomic event, but licensed merchandise has a funny way of revealing where household spending still has a pulse. Paladone Products has put its first LEGO-branded collection into stores, a modest-looking launch with some real retail logic behind it. This is not a grand toy-box bet on one blockbuster item. It is a spread of...

Continue Reading
Schloss Johannisberg Leads 2026 Global Vineyard List

Updated Category News Views 17

A 1,200-year-old riesling estate just beat the world at being memorable. Schloss Johannisberg in Germany’s Rheingau has taken No. 1 in The 50 Best Vineyards 2026, moving up from No. 2 last year and also claiming Best Vineyard in Europe. For anyone watching the wine business from the outside, this is not really a story about one bottle edging out another. It is a...

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 121

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading

Top 5 Most Recently Viewed Articles

Nvidia's Strategic Path in AI and Future Possibilities

Updated Category News Views 133

Nvidia's rise as a leader in artificial intelligence was no accident. The tech giant smashed revenue and profit records that had traders buzzing back then. Everyone who jumped on Nvidia over the past couple of years likely scored some serious gains. But here's where it gets tricky: what’s next? Long-term thinking is crucial; it's one thing to ride the wave when...

Continue Reading
Exploring the Rise of AvaTrade and Its User-Friendly App

Updated Category News Views 167

Understanding AvaTrade – A Comprehensive Trading Platform AvaTrade is a highly regarded global trading platform founded to offer access to a variety of financial markets. With licenses from multiple recognized regulatory bodies, the platform ensures high standards of transparency and investor protection, allowing users to engage in trading with confidence. Wide Range of...

Continue Reading
Honka Fusion+: A Breakthrough in Sustainable Wood Construction

Updated Category News Views 192

Honka Fusion+: A Breakthrough in Sustainable Wood Construction Honka, a leader in the realm of modern wood construction, has recently introduced an exciting innovation in the form of Honka Fusion+. This new generation of non-settling CLT (cross-laminated timber) logs is set to revolutionize the construction industry by pushing the boundaries of what can be achieved with...

Continue Reading
Analyzing Recent Trading Trends for Honeywell International

Updated Category News Views 152

Understanding Current Options Trading Dynamics for Honeywell Intl Investors with significant financial resources have recently exhibited a bullish sentiment towards Honeywell International (NASDAQ: HON). This trend is noteworthy and should certainly be on the radar of market participants. Our observations from the public options data highlight this noticeable movement...

Continue Reading
Lineage, Inc. Faces Class Action Lawsuit Over Fraud Allegations

Updated Category News Views 217

Investors Encouraged to Act on Lineage, Inc. Class Action In light of recent developments, investors in Lineage, Inc. are strongly urged to engage with Kirby McInerney LLP regarding a class action lawsuit stemming from alleged securities fraud. This legal action is specifically focused on investors who acquired Lineage securities during a defined period, particularly...

Continue Reading